CA2572729C - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof - Google Patents

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof Download PDF

Info

Publication number
CA2572729C
CA2572729C CA2572729A CA2572729A CA2572729C CA 2572729 C CA2572729 C CA 2572729C CA 2572729 A CA2572729 A CA 2572729A CA 2572729 A CA2572729 A CA 2572729A CA 2572729 C CA2572729 C CA 2572729C
Authority
CA
Canada
Prior art keywords
extended release
pramipexole
tablet formulation
release tablet
water swelling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2572729A
Other languages
French (fr)
Other versions
CA2572729A1 (en
Inventor
Thomas Friedl
Wolfram Eisenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2572729(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CA2736965A priority Critical patent/CA2736965C/en
Publication of CA2572729A1 publication Critical patent/CA2572729A1/en
Application granted granted Critical
Publication of CA2572729C publication Critical patent/CA2572729C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Description

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof FIELD OF THE INVENTION

The present invention is directed to an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof.

BACKGROUND OF THE INVENTION

Pramipexole is a known dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g. bromocriptine or pergolide. It is also pharmacologically unique in that it is a full agonist and has receptor selectivity for the dopamine D2 family of dopamine receptors.

Pramipexole is designated chemically as (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole and has the molecular formula C10H17N3S and a relative molecular mass of 211.33. The chemical formula is as follows:

NHz S

H
The salt form commonly used is pramipexole dihydrochloride monohydrate (molecular formula C10H21C12N30S; relative molecular mass 302.27). Pramipexole dihydrochloride monohydrate is a white to off- white, tasteless, crystalline powder. Melting occurs in the range of 296 C to 301 C, with decomposition. Pramipexole is a chiral compound with one chiral centre. Pure (S)-enantiomer is obtained from the synthetic process by chiral recrystallization of one of the intermediates during synthesis.

Pramipexole dihydrochloride monohydrate is a highly soluble compound. Water solubility is more than 20 mg/ml and solubility in buffer media is generally above 10 mg/ml between pH 2 and pH 7.4. Pramipexole dihydrochloride monohydrate is not hygroscopic, and of highly crystalline nature. Under milling the crystal modification (monohydrate) does not change. Pramipexole is very stable in the solid state, yet in solution it is light sensitive.

Pramipexole immediate release (IR) tablets were first authorised in the USA in 1997, followed over the course of the next years by marketing authorisations in the European Union (EU), Switzerland, Canada and South America as well as in countries in Eastern Europe, Near East and Asia.

Pramipexole IR tablets are indicated in the EU and US for the treatment of signs and symptoms of either early parkinson's disease or advanced parkinson's disease in combination with levodopa. The IR tablets have to be taken 3 times a day.

From the pharmacokinetic point of view pramipexole IR tablets are rapidly and completely absorbed following oral administration. The absolute bioavailability is greater than 90%
and the maximum plasma concentration occurs within 1 to 3 hours. The rate of absorption is reduced by food intake but not the overall extent of absorption.
Pramipexole shows linear kinetics and a relatively small inter-patient variation of plasma levels. The elimination half- life (t1/2 [h]) varies from 8 hours in the young to 12 hours in the elderly.
As commonly known, modified release of active ingredient(s) allows to simplify the patient's administration scheme by reducing the amount of recommended daily intakes, improves patient's compliance, and attenuates adverse events, e.g. related to high plasma peaks. Modified release pharmaceutical preparations regulate the release of the incorporated active ingredient or ingredients over time and comprise formulations with a controlled, a prolonged, a sustained, a delayed, a slow or an extended release, so they accomplish therapeutic or convenience objectives not offered by conventional dosage forms such as solutions or promptly dissolving dosage forms.
A modified or extended release of active ingredient(s) from a pharmaceutical preparation may be accomplished by homogeneously embedding said active ingredient(s) in a hydrophilic matrix, being a soluble, partially soluble or insoluble network of viscous, hydrophilic polymers, held together by physical or chemical entanglements, by ionic or crystalline interactions, by complex formation, by hydrogen bonds or van der Waals forces.
Said hydrophilic matrix swells upon contact with water, thereby creating a protective gellayer from which the active ingredient(s) is (are) slowly, gradually, continuously released in time either by diffusion through the polymeric network, by erosion of the gellayer, by dissolution of the polymer, or by a combination of said release mechanisms.
However, it has proved difficult to formulate a tablet having a suitable combination of modified, extended or sustained-release and handling properties, where the drug is one having relatively high solubility, as in the case of pramipexole dihydrochloride.

There are a number of approaches described in prior art to provide sustained release tablet compositions of pramipexole:

WO 2004/010997 describes a sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising a water- soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cn 2, preferably at least about 0.175 kN cn 2, and more preferably at least about 0.2 kN cm 2, at a solid fraction representative of the tablet. The disclosure thereof is concentrated to provide a composition with sufficient hardness yield during a high-speed tableting operation, in particular to resist erosion during application of a coating layer.
According to a preferred embodiment it is provided a pharmaceutical composition in a form of an orally deliverable tablet having a core comprising pramipexole dihydrochloride monohydrate in an amount of about 0.375, 0.75, 1.5, 3 or 4.5 mg, dispersed in a matrix comprising (a) HPMC type 2208 in an amount of about 35% to about 50% by weight of the tablet and (b) a pregelatinized starch having a tensile strength of at least about 0.15 kN
cm 2 at a solid fraction of 0.8, in an amount of about 45% to about 65% by weight of the tablet; said core being substantially enclosed in a coating that constitutes about 2% to about 7% of the weight of the tablet, said coating comprising an ethylcellulose-based hydrophobic or water- insoluble component and an HPMC-based pore-forming component in an amount of about 10% to about 40% by weight of the ethylcellulose-based component.
Furthermore, WO 2004/010999 discloses an orally deliverable pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose oral administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. However, in practical use, it appears that any formulation having an extended or controlled release profile designed for a once daily application would meet the above requirements for which a general teaching how to adjust such a profile is missing.

It is an object of the present invention to provide a controlled release tablet composition of pramipexole or a pharmaceutically acceptable salt thereof that is suitable for once- daily oral administration. It is a further object to provide a tablet composition comprising pramipexole or a pharmaceutically acceptable salt thereof that provides a day-long therapeutic effect and will allow patients to treat their symptoms with a single daily dose, which makes it possible to adjust the release profile of the active ingredient according to a selected release profile dependent or independent from the pH values.
Furthermore a method of manufacturing the tablet formulation shall be provided.

DESCRIPTION OF THE INVENTION

Surprisingly, it has been found that pramipexole or a pharmaceutically acceptable salt thereof may be used in formulations as once daily extended (or slow) release tablets and two alternative formulation principles allow different release rate types dependent or independent from the pH value.

The present invention relates to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Preferably the invention relates to an extended release tablet formulation, wherein the matrix 5 comprises at least two water swelling polymers other than pregelatinized starch, and wherein at least one of the at least two polymers is an anionic polymer.

Also preferred is an extended release tablet formuhtion, wherein the anionic polymer is selected from the group of optionally crosslinked acrylic acid polymers, methacrylic acid polymers, alginates, and carboxymethylcellulose.

Also preferred is an extended release tablet formuhtion, wherein the anionic polymer is an optionally crosslinked acrylic acid polymer, and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 0.25 wt.-% to about 25 wt.-%, and preferably from about 0.5 wt.-% to about 15 wt.-%, and preferably from about 1 wt.-% to about 10 wt.-%.

Also preferred is an extended release tablet formuhtion, wherein at least one of the at least two polymers is a substantially neutral polymer other than pregelatinized starch.

Also preferred is an extended release tablet formuhtion, wherein the substantially neutral polymer is selected from hydroxypropylcellulose and hydroxypropylmethylcellulose.

Particularly preferred is an extended release tablet formuhtion , wherein the substantially neutral polymer is hydroxypropyl methylcellulose, and wherein the content of hydroxypropyl methylcellulose in the matrix is from about 10 wt.-% to about 75 wt.-% and preferably from about wt.-% to about 65 wt.-%.

Particularly preferred is an extended release tablet formuhtion, wherein the matrix comprises about:
(a) pramipexole or a salt thereof 0.05 to 5 wt.-%
25 (b) anionic water swelling polymer(s) 0.25 to 25 wt.-%
(c) neutral water swelling polymer(s) 10 to 75 wt.-%
(d) further excipients ad 100 wt.-%

Particularly preferred is an extended release tablet formulation consisting of Pramipexole-dihydrochloride monohydrate, Hypromellose 2208, Corn starch, Carbomer 941, Colloidal silicon dioxide and Magnesium stearate.

25771-1316(S) A preferred embodiment of the present invention relates to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprisinu (a) at least one water swelling polymer Other than pregelatlnized starch and optionally excipients; the resulting tablet providing a pH-independent in nitro release characteristic in the range from pH l to 7.5, or (b) at least one water swelling anionic polymer and optionally excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5.
Most preferably the present invention relates to a matrix of the extended release tablet formulation comprising at least one water swelling polymer other than pregelatinized starch, preferably a water swelling essentially neutral polymer, a water swelling anionic polymer and optionally excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.

Also preferred is an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least two water swelling polymers other than pregelatinized starch, and wherein at least one of the least two polymers is an anionic polymer and optionally further excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5.

25771-1316(S) 6a The extended release formulations according to the present invention intended for oral administration allow to select and estimate which in vitro release characteristic and timing of a formulation is most suitable to achieve the desired in vivo plasma profiles preferably with a once daily application. Therefore, a formulation principle with several variants has been developed for a single unit matrix tablet, i.e. formulations having different release rate types are provided and a different pH dependency is available. These alternative formulations are beneficial to patients as the extended release drug delivery will allow patients to treat their symptoms with a single daily dose. thereby increasing patient conveilience and compliance.

The terns in vitro release characteristic" as used hereinbefore or hereinafter is directed to a release characteristic as obtained in a kind of nornlally used liquid medium for in vitro experiments wherein the release of active ingredient from the extended release formulation can occur, i.e. for example in in vitro dissolution media, but also in body fluids or simulated body fluids, more in particular in the gastro-intestinal fluids.

In the frame of the present invention the term "extended" release should be understood in contrast to an immediate release, the active ingredient is gradually, continuously liberated over time, sometimes slower or faster, dependent or independent from the pH
value. In particular, the term indicates that the formulation does not release the full dose of the active ingredient immediately after oral dosing and that the formulation allows a reduction in dosage frequency, following the definition for extended release, interchangeable with slow release. A slow or extended release, used synonymously with prolonged action, sustained release, or modified release, dosage form is a dosage form that allows a reduction in dosing frequency or a significant increase in patient compliance or therapeutic performance as compared to that presented as a conventional dosage form (e.g.
as a solution or an immediate drug-releasing, conventional solid dosage form).

A release characteristic which is pH-independent indicates that the release characteristic is virtually the same in different pH media.

According to the teaching of the present invention, extended release tablet formulations are provided with different in vitro release profiles.

The extended release tablets of the present invention are believed to apply a swelling and partly eroding polymer matrix. Based on the assumed mechanisms, the release profile may roughly follow a square root of time to exponential in vitro release characteristic.
Depending on the particular embodiment formulation a) is widely independent from the pH
value in the range from pH 1 to 7.5, and formulation b) is faster in simulated gastric juice having a pH < 4.5 but are independent from the pH value in the range from 4.5 to 7.5. A
faster release in simulated gastric juice versus slower release in the intestinal fluid can be advantageous in cases where a loading dose effect from the dosage form is desired, whereas a widely pH independent release profile can be advantageous to reduce the risk of dose dumping and food effects.
According to the present invention under "formulation a)" is understood the tablet formulation wherein the matrix comprises the composition as above-defined under a) and under "formulation b)" is understood the tablet formulation wherein the matrix comprises the composition as above-defined under b).

The water swelling polymer of the present invention represents at least one hydrophilic water swelling polymer constituting the extended release matrix which slowly releases the pramipexole or its salt as active ingredient. The polymer swells upon contact with aqueous fluid following administration, resulting in a viscous, drug release regulating gellayer. The viscosity of the polymer preferably ranges from 150 to 100,000 mPa.s (apparent viscosity of a 2% aqueous solution at 20 C.).

Examples of such polymers are water swelling substantially neutral polymers or water swelling anionic polymers.
The term "water swelling substantially neutral polymers" of the present invention comprises alkylcelluloses, such as, methylcellulose; hydroxyalkylcelluloses, for example, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose; hydroxyalkyl alkylcelluloses, such as, hydroxyethyl methylcellulose and hydroxypropyl methylcellulose; carboxyalkylcellulose esters; other natural, semi-synthetic, or synthetic di-, oligo- and polysaccharides such as galactomannans, tragacanth, agar, guar gum, and polyfructans; methacrylate copolymers;
polyvinylalcohol; polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; combinations of polyvinylalcohol and polyvinylpyrrolidone;
polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, preferably cellulose ether derivatives such as hydroxypropyl methylcellulose and hydroxypropyl cellulose, most preferred hydroxypropyl methylcellulose.

The term "water swelling anionic polymer" of the present invention comprises acrylic acid polymerisate, methacrylic acid copolymers, alginates, carrageenans, acacia, xanthan gum, chitin derivates such as chitosan, carmellose sodium, carmellose calcium, preferably acrylic acid polymerisate.
Different viscosity grades of hydroxypropyl cellulose and hydroxypropyl methylcellulose are commercially available. Hydroxypropyl methylcellulose (HPMC) preferably used in the present invention has a viscosity grade ranging from about 3,500 mPa.s to about 100,000 mPa.s, in particular ranging from about 4,000 mPa.s to about 20,000 mPa.s and most in particular a viscosity grade of about 6,500 mPa.s to about 15,000 mPa.s (apparent viscosity ofa 2% aqueous solution at 20 C.), e.g. hypromellose 2208 or 2206 (DOW, Antwerp, Belgium). HPMC type 2208 contains 19-24% by weight methoxy and 4-12%
by weight hydroxvpropoxy substituents.

Hydroxypropyl cellulose having a viscosity higher than 1,500 mPa.s (apparent viscosity of a 1 % aqueous solution at 20 C) is preferred, in particular hydroxypropy]
cellulose having a viscosity in the range from about 1500 to about 3000 mPa.s, preferably from 4000 to 6500 mPa.s (2% aqueous solutions), e.g. the Klucel'" series such as Klucel" M
(Hercules, Wilmington, USA).

Without wishing to be bound by theory, there are believed to exist three main mechanisms by which pramipexole or a salt thereof can be released from a hydrophilic matrix:
dissolution, erosion and diffusion. Pramipexole or its salt will be released by the dissolution mechanism when it is homogeneously dispersed in a matrix network of a soluble polymer. The network will gradually dissolve in the gastrointestinal tract, thereby gradually releasing its load. The matrix polymer can also gradually be eroded from the matrix surface, likewise releasing pramipexole or its salt in time. When pramipexole is processed in a matrix made up of an insoluble polymer, it will be released by diffusion: the gastro-intestinal fluids penetrate the insoluble, sponge-like matrix and diffuse back out loaded with drug.

'1'hereforc, the water swel ling polymers constituting the matrix, particularly in a matrix according to formulation a), mainly provide for the controlled phannacokinetic release profile of the preparation. Depending on the amount of water swelling polymer(s) processed in the preparation, the release profile can be tuned, i.e. larger amounts of swelling polymer lead to a more pronounced sustained release effect and vice versa.
Preferably, the amount of water swelling polymer in the present formulation ranges from about 10 to about 80% by weight.

In addition, when using a combination of polymers, the ratio of said polymers also influences the release profile of the preparation. A combination of different polymers 5 offers the possibility of combining different mechanisms by which pramipexole is released from the matrix. Such combination facilitates control of the pharmacokinetic release profile of the preparation at will. For example, when using one or more water swelling polymers, in particular hydroxypropyl cellulose and hydroxypropyl methylcellulose, the weight percentage of hydroxypropyl methylcellulose preferably ranges from 25 to about 10 62%; the weight percentage of hydroxypropyl cellulose preferably ranges between 0% and about 16%.
Release of pramipexole or a salt thereof from a matrix containing hydroxypropyl cellulose and hydroxypropyl methylcellulose occurs by a combined set of release mechanisms. Due to the higher solubility of hydroxypropyl methylcellulose compared with hydroxypropyl cellulose, the former will gradually dissolve and erode from the matrix, whereas the latter will more act as a sponge- like matrix former releasing the active ingredient mainly by diffusion.

The extended release tablet formulation according to formulation a) is pH-independent.
Therefore, the disadvantage that food related dose-dumping may be encountered is avoided.
The problem of food related dose-dumping in fed patients can be attributed to a lot of factors such as the mechanical forces that are exerted by the stomach on its content and thus on an ingested preparation as well as the different pH regions of the gastro-intestinal tract. Since the pH values encountered in the gastro- intestinal tract vary not only with the region of the tract, but also with the intake of food, an extended release formulation preferably also has to provide an extended release profile and in particular has to avoid dose-dumping regardless whether the patient is in fasted or fed conditions.

According to the present invention the oral extended release formulation a) retains its pharmacokinetic release profile along its way through the gastro- intestinal tract so as to avoid undesirable fluctuations in drug plasma concentrations or complete dose-dumping, in particular avoids dose-dumping in different regions of the gastro- intestinal tract.
Beside pramipexole or a salt thereof, and the water swelling polymer(s), the formulation of the present invention may also optionally comprise further excipients, i.e.
pharmaceutically acceptable formulating agents, in order to promote the manufacture, compressibility, appearance and taste of the preparation. These formulating agents comprise, for example, diluents or fillers, glidants, binding agents, granulating agents, anti-caking agents, lubricants, flavors, dyes and preservatives. Other conventional excipients known in the art can also be included.

The filler may be selected from soluble fillers, for example, sucrose, lactose, in particular lactose monohydrate, trehalose, maltose, mannitol and sorbitol. Different grades of lactose can be used. One type of lactose preferably used in the present invention is lactose mono hydrate 200 mesh (DMV, Veghel, The Netherlands). Another lactose monohydrate, lactose monohydrate of the type DCL 11 (DMV, Veghel, The Netherlands), can also preferably be used. The notation DCL refers to "Direct Compression Lactose".
The number 11 is a reference number of the manufacturer. In case of a water soluble active ingredient, like the one described in this invention, more preferably water insoluble fillers, such as starch and starch derivates other than pregelatinized starch, e.g. corn starch, potato starch, rice starch or wheat starch, microcrystalline cellulose, dibasic calcium phosphate dihydrate and anhydrous dibasic calcium phosphate, preferably corn starch, can be used in addition or instead of the water soluble fillers. The total weight percentage of filler ranges between about 5% and about 75% by weight.

A glidant can be used to improve powder flow properties prior to and during tableting and to reduce caking. Suitable glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, talc, tribasic calcium phosphate and the like. Colloidal silicon dioxide is preferably included as a glidant in an amount up to about 2%, preferably about 0.2% to about 0.8%, by weight of the tablet.

A lubricant can be used to enhance release of a tablet from apparatus on which it is formed, for example by preventing adherence to the face of an upper punch ("picking") or lower punch ("sticking"). Suitable lubricants include magnesium stearate, calcium stearate, canola oil, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, polyethylene glycol, polyvinyl alcohol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate and the like. In one embodiment, magnesium stearate is included as a lubricant in an amount of about 0.1% to about 1.5%, preferably about 0.3% to about 1%, by weight of the tablet.

Among the optional formulating agents that further may be comprised in the matrix formulation there may be mentioned agents such as polyvidone; copovidone;
starch;
acacia; gelatin; seaweed derivatives, e.g. alginic acid, sodium and calcium alginate;
cellulose, preferably microcrystalline cellulose, cellulose derivatives, e.g.
ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, having useful dry or wet binding and granulating properties; and antiadherents such as talc and magnesium stearate.
According to a preferred embodiment of the present invention the matrix of the extended release tablet formulation of alternative a) comprises or essentially consists of hydroxypropyl methylcellulose, such as hypromellose, and further excipients.
The amount of hydroxypropyl methylcellulose is preferably in the range from 10 to 75%, particularly preferred from 25 to 65% most preferred from 35 to 55% by weight. The amount of further excipients is preferably in the range from 90 to 25%, particularly preferred from 75 to 35%, most preferred from 65 to 45 % by weight.

The expression "consisting essentially" is understood in the sense that it does not in principle exclude the presence, in addition to the mandatory components mentioned, of other components, the presence of which does not affect the essential nature of the formulation.
In some embodiments of the present invention it is provided a pH-dependent release profile, the release of pramipexole or its salt from the tablet and subsequent the absorption into the blood stream can vary during the passage of the dosage form along the gastro-intestinal tract. Thus, formulation b) provides a pH-dependent release characteristic wherein the release characteristic in the range of pH < 4.5 is faster and a slower and further on pH-independent release characteristic in the range from 4.5 = pH = 7.5.
The above details for the water swelling polymer and selection and type of optional excipients may apply to formulation b), too.

Moreover, an anionic water swelling polymer, preferably an acrylic acid polymerisate is mandatorily present in formulation b), which is preferably selected from carbomer or Carbopol' series, known acrylic acid polymerisates having high molecular weights.
Particularly preferred are for example carbomer 941 (Carbopol~' 71 G, Carbopol ' 971) and carbomer 934 (Carbopol 974). The acrylic acid polymerisate is preferably present in the range of 0.25 to 25% by weight, particularly preferred 0.5 to 15% by weight, most preferred 1 to 10% by weight. The pl-l dependency of formulation b) results from the presence of an anionic water swelling polymer, particularly preferred from the presence of acrylic acid polymerisate which intends to swell in a greater extent in the acid pH range above pH 4.5 and in the alkaline pH range.

An increasing amount of acrylic acid leads to a decrease of the release rate.
Therefore, adjusting the amount of acrylic acid polymerisate makes it possible to further tune the dissolution profiles as desired. To adjust the amount of acrylic acid polymerisate in the preferred range from 0.25 to 25 % by weight provides the further advantage that the desired, resp. matching, dissolution profiles can be adjusted, resp.
maintained, for a variety of formulations composed of different amounts and/or types of gel-forming agents, water swelling polymers, fillers, and dry binders.

According to a preferred embodiment of the present invention the matrix of the extended release tablet formulation comprises or essentially consists of hydroxypropyl rnethylcellulose, acrylic acid polymerisate and further excipients. The amount of hydroxypropyl methylcellulose is preferably in the range from 10 to 75%, particularly preferred from 25 to 65%, most preferred from 35 to 55% by weight. The amount of acrylic acid polymerisate is preferably as above-mentioned. The amount of additional excipients is preferably in the range from 90 to 25% particularly preferred from 75 to 35%, most preferred from 65 to 45% by weight. Optionally carboxymethylcelIulose sodium may additionally be present preferably in the range from 5 to 50%, particularly preferred from 10 to 40%. most preferred from 15 to 30% by weight, As active ingredient, pramipexole or a pharmaceutically acceptable salt thereof, may be present in any amount suitable for the desired treatment of a patient. A
preferred salt of pramipexole is the dihydrochloride salt, most preferably in the form of the monohydrate.
Usual amounts are from about 0.1 to about 5 mg pramipexole salt. According to a particularly preferred embodiment e.g. 0.750 mg pramipexole dihydrochloride monohydrate, corresponding to 0.524 mg anhydrous base, is used in the extended release tablet formulation according to the present invention. However, any other amount of active ingredient suitable for treatment may be used with the only proviso that the amount of pramipexole or salt is sufficient to provide a daily dose in one to a small plurality, for example one to about 4, of tablets to be administered at one time. Preferably the full daily dose is delivered in a single tablet. An amount of pramipexole salt, expressed as pramipexole dihydrochloride monohydrate equivalent, of about 0.1 to about 10 mg per tablet, or about 0.05% to about 5% by weight of the composition, will generally be suitable.
Preferably an amount of about 0.2 to about 6 mg, more preferably an amount of about 0.3 to about 5 mg, per tablet is present. Specific dosage amounts per tablet e.g.
include 0.375, 0.5, 0.75, 1.0, 1.5, 3.0 and 4.5 mg pramipexole dihydrochloride monohydrate.
The amount that constitutes a therapeutically effective amount varies according to the condition being treated, the severity of said condition, and the patient being treated.

An extended release tablet formulation according to the present invention, , has preferably the following composition:

pramipexole or a salt thereof 0.05 to 5% by weight water swelling polymer(s) 10 to 75% by weight acrylic acid polymerisate 0 to 25% by weight optional further excipient(s) ad 100% by weight.
Therefore, a particularly preferred extended release tablet formulation of the present invention consists of 0.1 to 2% by weight of pramipexole or a salt thereof;
25 to 65% by weight of hydroxypropyl methylcellulose;
0 to 40% by weight of carboxymethylcellulose sodium;
0 to 75% by weight of corn starch other than pregelatinized starch;

0 to 15% by weight of acrylic polymerisate, preferably carbomer 941;
0.5 to 50% by weight of excipients, preferably selected from the group consisting of colloidal silicon dioxide, magnesium stearate, lactose monohydrate, mannitol, microcrystalline cellulose, dibasic anhydrous calcium phosphate, hydroxyproylcellulose, 5 povidone, copovidone, talc, macrogols, sodium dodecylsulfate, iron oxides and titanium dioxide.
According to the present invention starch other than pregelatinized starch, preferably corn starch if present, may impart several functions at the same time such as filler, glidant, and the like. However, it may be preferred to exclude starch completely from the tablet 10 formulation according to the present invention, which may be replaced by one or more of the above- mentioned other excipient(s). Furthermore, a starch having a tensile strength of at least about 0.15 kN cm 2 at a solid fraction representative of the tablet as claimed according to WO 2004/010997 is not required according to the present invention.
15 It is preferred that no coating is present on the tablet formulation according to the present invention. However, the extended release tablet of the invention may comprise a nonfunctional coating. A nonfunctional coating can comprise a polymer component, for example HPMC, optionally with other ingredients, for example one or more plasticizers, colorants, etc. The term "nonfunctional" in the present context means having no substantial effect on release properties of the tablet, and the coating serves another useful purpose. For example, such a coating can impart a distinctive appearance to the tablet, provide protection against attrition during packaging and transportation, improve ease of swallowing, and/or have other benefits. A nonfunctional coating should be applied in an amount sufficient to provide complete coverage of the tablet. Typically an amount of about 1% to about 10%, more typically an amount of about 2% to about 5%, by weight of the tablet as a whole, is suitable.

The tablets of the present invention can be of any suitable size and shape, for example round, oval, polygonal or pillow-shaped, and optionally bear nonfunctional surface markings. According to the present invention it is preferred that the extended release tablets are white to off- white and of oval or round, biconvex, shape.

Tablets of the invention can be packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions and adverse reactions.

The present invention is further directed to the use of the extended release tablet formulation according to the present invention for preparing a medical composition for the treatment of parkinson's disease and complications or disorders associated therewith.
Furthermore, the present invention is preferably directed to a method of manufacturing the extended release tablet formulations via a direct compression process comprising the steps of (1) producing an active ingredient trituration wherein the active ingredient is pramipexole or a pharmaceutically acceptable salt thereof by preblending it with a portion of water swelling polymer(s) and/or further excipient(s) in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled, preferably peg milled, prior to use;

(2) premixing the active ingredient trituration of step (1), the main portion of the water swelling polymer(s) and/or excipients in a mixer to obtain a pre- mixture;
(3) optionally dry screening the pre-mixture through a screen in order to segregate cohesive particles and to improve content uniformity;

(4) mixing the pre- mixture of step (2) or (3) in a mixer, optionally by adding remaining excipients to the mixture and continuing mixing; and (5) tableting the final mixture by compressing it on a suitable tablet press to produce matrix tablets.

Therefore, the tablets are manufactured via a direct compression process which applies to both types of pramipexole extended release matrix tablets. To achieve adequate content uniformity in this low drug load formulation, the active ingredient is preferably peg- milled.
Preferably the particle size distribution of the peg- milled drug substance, as determined by laser diffractometry using a dry dispensing system, is characterized by particle fraction of 90 % (V/V) being smaller than 100 pm, most preferably a particle fraction of 90 % (V/V) being smaller than 75 pin in diameter.

Also other processes can be applied to the manufacturing of Pramipexole extended release tablets, like conventional wet granulation and roller compaction. In case of wet granulation preferably Pramipexole is granulated with suitable fillers, like e.g. starches other than pregelatinized starch, microcrystalline cellulose, lactose monohydrate or anhydrous dibasic calcium phosphate, and wet binding agents, like e.g.
hydroxypropylmethylcellulose, hydroxypropylcellulose, povidone, copovidone, and starch paste, leading to a active ingredient concentrate, which after drying and dry screening is mixed with the main fraction of go] forming excipients, like all the above described retarding principles.
In case of roller compaction, or in other words dry granulation, either a premix of Pramipexole with part of the excipients used in the direct compression process, or the complete mixture containing all excipients, is processed through a conventional roller compactor to form ribbons, which are thereafter screened down to granules which are finally mixed with other excipients, like glidants, lubricants and antiadherents.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a flow diagram illustrating a preferred embodiment of the direct compression manufacturing process according to the present invention;

Figure 2 is a graph illustrating the dissolution profiles ofa matrix tablet formulation according to the present invention which contains 4% by weight Carbopol in 3 different pH media; and Figure 3 is a graph illustrating the dissolution profiles of 3 matrix tablet formulations according to the present invention which contain 0% , 1 % and 4% by weight of Carbopol``', respectively.

Figure 1 illustrates a preferred embodiment of the manufacturing process with reference to a flow diagram wherein the manufacture of the extended release tablets of Examples I and = 25771-1316 2 are exemplarily shown. Figure 1 shows the detailed process steps and the in process controls performed.

Process step (1) is directed to the active ingredient trituration, i.e. in the present case a salt of pramipexole, pramipexole dihydrochloride monohydrate, in peg-milled quality, is preblended with a portion of the polymer, in this case hydroxypropyl methylcellulose, in a commonly known mixer. In the flow chart a Turbula`" free-fall mixer or blender is used. The mixing time is several minutes, in the present case preferably 10 min.

In process step (2) according to the flow chart a premixing is performed, wherein the active ingredient trituration and the main portion of the water swelling polymer(s) and excipients are premixed for several minutes to obtain a pie-mix. In the present case the main portion of hydroxypropyl methylcellulose (hypromellose), corn starch, carbomer 941 and colloidal silicon dioxide are premixed for 5 min. in the above-mentioned Turbula"' mixer or blender.
According to the following process step (3) a dry screening may optionally take place. The pre-mixture may be manually screened through a screen, for example a 0.8 tnm mesh size screen. in order to segregate cohesive particles and to improve content uniformity.

In the subsequent process step (4) the main mixing step is performed according to which the components are mixed for several minutes, preferably 5 min. in the Turbula'" mixer after screening. Optionally further excipients may be added at this time, in the flow chart the component magnesium stearate is added to the main mixture, and further mixing for several minutes, e.g. 3 min., in the Turbula'"' mixer is performed (final mixing) to obtain the final mixture.

Process step (5) of the process according to the present invention is the tableting. The final mixture is compressed on a suitable tablet press to produce. for example, oblong shaped matrix tablets (ER tablets = extended release tablets). In order to control and maintain the required quality the obtained matrix tablets are subjected to the following in-process controls: tablet mass, hardness, tablet height and friability.

= r 25771-1316 The obtained pramipexole extended release tablets of the present invention may then be filled, for example, into High Density Polyethylene (HDPE) bottles. The bottles are closed tightly with screw caps and appropriately labelled, whereby all packaging and labelling activities are performed according to cGMP regulations. Alternatively, a blister type packaging can be used, e.g. using aluminium/aluminium foil blisters.

Figure 2 represents a graph illustrating the dissolution profiles of a matrix tablet formulation according to the present invention. The matrix tablet contains 4%
by weight Carbopol`"`, the detailed composition is given in Example 2 . The release characteristics of the matrix tablet in 3 different pH media are shown, i.e. in 0.05 M phosphate buffer, pI1 =
6.8, n = x, in simulated gastric juice, pH - 1.2, n = x, and in Mcllvaine buffer, pH = 4.5, n _ x (x ... represents the number of units tested). The value percent of released active ingredient is plotted against the time (hours).

Figure 3 represents a graph illustrating the dissolution profiles of 3 matrix tablet formulations according to the present invention. The matrix tablets contain no Carbopol', I% or 4% by weight Carbopol , respectively, the detailed compositions are given in Examples 1, 2 and 4. The medium is a 0.05 M phosphate buffer, pl I = 6.8. The value percent of released active ingredient is plotted against the time (hours).
Figures 2 and 3 show a pH-independent in nitro release characteristic in the range from pH
1 to 7.5 in case Carbopol is not present and a pH-dependent release characteristic wherein the release characteristic in the range of pH < 4.5 is faster in case Carbopol is present. An increase of the amount of Carbopol' leads to a decreased releasing rate.
The advantages of the present invention are manifold:
According to the present invention, extended release tablets containing pramipexole or its salt are available showing different in vitro release profiles. It is possible to select a tailor-made release characteristic for patient's needs, symptoms and clinical picture observed.
The primary indication for prarnipexole, Parkinson's disease, is an affliction that becomes more prevalent with advancing age and is often accompanied by decline in memory.
Therefore, the matrix tablets according to the present invention providing an extended or slow release of pramipexole or a salt thereof allows to simplify the patient's administration scheme by reducing the amount of recommended daily intakes and improves patient's compliance, particularly relevant for elderly patients. The inventive extended release tablet formulation provides a daily dose preferably administered at one time.

Furthermore, the tablets of the present invention may be manufactured via a direct compression, wet or dry granulation process which applies to both types of extended release matrix tablets.

10 The invention described will now be illustrated by the Examples which follow various other embodiments and will become apparent to the skilled person from the present specification. However, it is expressly pointed out that the Examples and description are intended solely as an illustration and should not be regarded as restricting the invention.
15 Examples According to the present invention pramipexole extended release tablets have been manufactured. The tablets of the Examples are white to off- white, 14 x 6.8 mm oblong shaped, biconvex tablets. The tablets are intended to be administered orally, and shall not be divided into halves. The pramipexole tablets in the Examples contain 0.75 mg of 20 pramipexole dihydrochloride monohydrate, corresponding to 0.524 mg of pramipexole free, anhydrous base.

= 25771-1316 Example 1 One embodiment of the qualitative and quantitative composition of pramipexole extended release tablets according to the present invention is shown in TABLE 1.
TABLE 1: Qualitative and quantitative composition of pramipexole extended release tablet mg per Ingredient 0.75 ing Function Reference to Standards tablet pramipexole-dihydrochloride 0.75 Active ingredient Corporate standard inonohydrate, peg-milled Hypromellose 2208 157.500 Swelling agent Ph.Eur. / USP
(Methocel' K 15 M) Corn starch 183.700 Filler Ph.Eur. / NF
Carbomer 941 (Carbo olT' 71 G) 3.50 Gelling agent Ph.Eur. / NF
Colloidal Silicon dioxide 2.80 Glidant Ph.Eur. / NF
Magnesium stearate 1.75 Lubricant Ph.Eur. / NF
Total 350.000 Example 2 A further embodiment of the qualitative and quantitative composition of pramipexole extended release tablets according to the present invention is shown in TABLE
2.
TABLE 2: Qualitative and quantitative composition of pramipexole extended release tablet mg per Ingredient 0.75 mg Function Reference to Standards tablet Pramipexole-dihydrochloride 0.750 Active ingredient Corporate standard rnonohydrate, peg-milled Hypromellose 2208 157.500 Swelling agent Ph.Eur. / USP
(Methocel" K 15 M) Corn starch 174.600 Filler Ph.Eur. / NF
Carbomer 941 (Carbopol `B' 71 G) 14.000 Gelling agent Ph.Eur. /NF
Colloidal Silicon dioxide 1.400 Glidant Ph.Eur. / NF
Magnesium stearate 1.75 Lubricant Ph.Eur. / NF
Total 350.000 The batch formula for the two pramipexole tablet formulations of Example I and 2 is shown in Table 3. The batch size of the final mixture corresponds to a batch size of 2000 tablets.
Table 3: Composition per batch of pramipexole 0.75 mg ER tablets Ingredient Grams per batch Grams per batch Example 1 Example 2 Pramipexole-dihydrochloride 1.500 1.500 monohydrate, peg-milled Hypromellose 2208 315.000 315.000 Corn starch 367.400 349.200 Carbomer 941 7.000 28.000 Colloidal Silicon dioxide 5.600 2.800 Magnesium stearate 3.500 3.500 Total Mass 700.000 700.000 Example 4 The following Example shows a pramipexole tablet formulation which corresponds to formulation a) providing a release characteristic independent in the pH range of I to 7.5.
'Table 4 Constituents mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2208 157.500 (Methoce)'" K 100 M) Corn starch 187.900 Colloidal silicon dioxide 2.100 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 5 The following Examples 6 to 14 show pramipexole tablet formulations which correspond to formulation b) providing a faster release characteristic for pH < 4.5.

Table 5 Constituents mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2208 175.000 (Methocel'"' K 15 M) Carbox}nnethylcellulose sodium 87.500 Lactose monohydrate (200 mesh) 52.500 Microcrystalline cellulose (grade PH 101) 31.100 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 6 Table 6 Constituents Mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2208 175.000 (Methocel" K 15 M) Carboxymethylcellulose sodium 87.500 Lactose monohydrate (200 mesh) 52.500 Microcrystalline cellulose (grade PH 101) 27.600 Carbomer 941 (Carbopol's 71 G) 3.500 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 7 Tablle7 Constituents Mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2208 175.000 (Mcthocei " K 15 M) Carboxymethylcellulose sodium 87.500 Lactose monohydrate (200 mesh) 45.500 Microcrystalline cellulose (grade PH 101) 24.100 Carbomer 941 (Carbopol6 710) 14.000 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 8 Table 8 Constituents mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Carbomer 941 (Carbopol ' 71 G) 87.500 Lactose monohydrate (200 mesh) 225.400 Microcrystalline cellulose (grade PH 101) 33.200 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 9 Table 9 Constituents mg/tablet Pramipexole- dihydrochloride monohydrate, peg- milled 0.750 Carbomer 941 (Carbopol 71 G) 70.000 Lactose monohydrate (200 mesh) 242.900 Microcrystalline cellulose (grade PH 101) 33.200 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 10 10 Table 10 Constituents mg/tablet Pramipexole- dihydrochloride monohydrate, peg- milled 0.750 Carbomer 941 (Carbopol 71 G) 70.000 Lactose monohydrate (200 mesh) 140.000 Calcium Phosphate, dibasic dihydrate 136.100 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 = 25771-1316 Example 11 Table 11 Constituents mg/tablet Pramipexole-di hydrochloride monohydrate, peg-milled 0.750 Carbomer 941 (Carbopol'"' 71 G) 52.500 Lactose monohydrate (200 mesh) 140.000 Calcium Phosphate, dibasic dihydrate 153.600 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 12 Table 12 Constituents mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2208 157.500 (Methocel'" K 15 M) Corn starch 163.400 Carbomer 941 (Carbopol 71 G) 24.500 Colloidal silicon dioxide 2.100 Magnesium stearate 1.750 Total weight matrix tablet 350.000 = = 25771-1316 Example 13 Table 0 Constituents rng/tablct Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hypromellose 2910 0.788 (Methocel'" E 5) Corn starch 173.812 Hypronlellose 2208 157.500 (Methocel' K 15 M) Carbomer 941 (Carbopol' 71 G) 14.000 Colloidal silicon dioxide 1.400 Magnesium stearate 1.750 Total weight matrix tablet 350.000 Example 14 Table 14 Constituents mg/tablet Pramipexole-dihydrochloride monohydrate, peg-milled 0.750 Hyprornellose 2208 148.500 (Methocel'" K 15 M) Corn starch 160.620 Carbomer 941 (Carbopol 71 G) 16.500 Colloidal silicon dioxide 1.980 Magnesium stearate 1.650 Total weight matrix tablet 330.000

Claims (39)

CLAIMS:
1. An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least two water swelling polymers other than pregelatinized starch, and wherein at least one of the at least two water swelling polymers is a water swelling anionic polymer.
2. The extended release tablet formulation of claim 1, wherein the water swelling anionic polymer is selected from the group of optionally crosslinked acrylic acid polymers, methacrylic acid polymers, alginates and carboxymethyicellulose.
3. The extended release tablet formulation of claim 1 or 2, wherein the water swelling anionic polymer is an optionally crosslinked acrylic acid polymer, and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 0.25 wt.-% to about 25 wt.-%.
4. The extended release tablet formulation of claim 1 or 2, wherein the water swelling anionic polymer is an optionally crosslinked acrylic acid polymer, and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 0.5 wt.-% to about 15 wt.-%.
5. The extended release tablet formulation of claim 1 or 2, wherein the water swelling anionic polymer is an optionally crosslinked acrylic acid polymer, and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 1 wt.-% to about 10 wt.-%.
6 The extended release tablet formulation of claim 1 or 2, wherein at least one of the at least two water swelling polymers is a water swelling substantially neutral polymer other than pregelatinized starch.
7. The extended release tablet formulation of claim 6, wherein the water swelling substantially neutral polymer is hydroxypropylcellulose or hydroxypropylmethylcellulose.
8. The extended release tablet formulation of claim 6 or 7, wherein the water swelling substantially neutral polymer is hydroxypropylmethylcellulose, and wherein the content of hydroxypropylmethylcellulose in the matrix is from about 10 wt.-% to about 75 wt.-%.
9. An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least two water swelling polymers other than pregelatinized starch, and wherein at least one of the least two polymers is an anionic polymer and optionally further excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5.
10. The extended release tablet formulation of claim 6, 7 or 8, wherein the matrix comprises about:

(a) pramipexole or a pharmaceutically acceptable salt thereof 0.05 to 5 wt.-%;

(b) water swelling anionic polymer(s) 0.25 to 25 wt.-%;

(c) water swelling substantially neutral polymer(s) 10 to 75 wt.-%;
and (d) further excipients ad 100 wt.-%.
11. The extended release tablet formulation of claim 6, 7, 8, 9 or 10, wherein the water swelling anionic polymer is an optionally cross-linked acrylic acid polymer.
12. The extended release tablet formulation of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, wherein the pramipexole is in the form of pramipexole dihydrochloride monohydrate.
13. The extended release tablet formulation of claim 6 consisting of pramipexole-dihydrochloride monohydrate, hypromellose 2208, corn starch, carbomer 941, colloidal silicon dioxide and magnesium stearate.
14 The extended release tablet formulation of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, which is for use once daily and wherein the contained amount of pramipexole or pharmaceutically acceptable salt thereof is sufficient to provide a daily dose of pramipexole or pharmaceutically acceptable salt thereof.
15. The extended release tablet formulation of claim 14 comprising 0.375 mg pramipexole dihydrochloride monohydrate.
16. The extended release tablet formulation of claim 14 comprising 0.75 mg pramipexole dihydrochloride monohydrate.
17. The extended release tablet formulation of claim 14 comprising 1.5 mg pramipexole dihydrochloride monohydrate.
18. The extended release tablet formulation of claim 14 comprising 3.0 mg pramipexole dihydrochloride monohydrate.
19. The extended release tablet formulation of claim 14 comprising 4.5 mg pramipexole dihydrochloride monohydrate.
20. Method of manufacturing an extended release tablet formulation as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 via a direct compression process comprising the steps of:

(1) producing an active ingredient trituration wherein the active ingredient is pramipexole or a pharmaceutically acceptable salt thereof by preblending it with a portion of the at least two water swelling polymers and/or further optional excipients in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled prior to use;

(2) premixing the active ingredient trituration of step (1), the main portion of the at least two water swelling polymers and further optional excipients in a mixer to obtain a pre-mixture;

(3) optionally dry screening the pre-mixture through a screen in order to segregate cohesive particles and to improve content uniformity;

(4) mixing the pre-mixture of step (2) or (3) in a mixer, and optionally adding remaining excipients to the mixture and continuing mixing; and (5) tableting the final mixture by compressing it on a suitable tablet press to produce matrix tablets.
21. Method of manufacturing an extended release tablet formulation as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 via a wet granulation process comprising the steps of:

(1) producing an active ingredient trituration wherein the active ingredient is pramipexole or a pharmaceutically acceptable salt thereof by blending it with a portion of suitable formulation excipients in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled prior to use;

(2) granulating the active ingredient trituration of step (1) by adding the granulation liquid;

(3) drying the granules of step (2) in a fluidized bed dryer or a drying oven;

(4) mixing the dried granules of step (3) with the at least two water swelling polymers and any remaining suitable formulation excipients in a mixer to obtain the final mixture;

(5) tableting the final mixture of step (4) by compressing it on a suitable tablet press to produce matrix tablets.
22. Method according to claim 21, wherein the granulation liquid is water.
23. Method of manufacturing the extended release tablet formulation according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 via a dry granulation process comprising the steps of:

(1) mixing the active ingredient pramipexole or a pharmaceutically acceptable salt thereof with either a portion or all of the at least two water swelling polymers and further optional excipients in a mixer, wherein pramipexole or the pharmaceutically acceptable salt thereof is milled prior to use;

(2) compaction of the mixture of step (1) on a suitable roller compactor;

(3) reducing the ribbons obtained during step (1) to small granules by suitable milling or sieving steps;

(4) optionally mixing the granules of step (3) with the remaining excipients in a mixer to obtain the final mixture;

(5) tableting the granules of step (3) or the final mixture of step (4) by compressing it on a suitable tablet press to produce matrix tablets.
24. Method according to claim 20, 21, 22 or 23, wherein the pramipexole or the pharmaceutically acceptable salt thereof is peg-milled prior to use.
25. Use of an extended release tablet formulation as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 for preparing a medical composition for the treatment of Parkinson's disease and complications or disorders associated therewith.
26. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
27. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
28. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
29. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
30. The extended release tablet formulation of claim 1, wherein the tablet comprises:

31. The extended release tablet formulation of claim 1, wherein the tablet comprises:

32. The extended release tablet formulation of claim 1, wherein the tablet comprises:

33. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
34. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
35. The extended release tablet formulation of claim 1, wherein the tablet comprises:

wherein the corn starch is other than pregelatinized starch.
36. Use of pramipexole dihydrochloride monohydrate in a tablet as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 for the treatment of Parkinson's disease
37. Use of pramipexole dihydrochloride monohydrate in a tablet as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 for the treatment of a complication or disorder associated with Parkinson's disease.
38. Use of pramipexole dihydrochloride monohydrate in a tablet as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 for the treatment of signs and symptoms of early Parkinson's disease or advanced Parkinson's disease.
39. Use of pramipexole dihydrochloride monohydrate in a tablet as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35, in combination with levodopa, for the treatment of signs and symptoms of early Parkinson's disease or advanced Parkinson's disease.
CA2572729A 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof Active CA2572729C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2736965A CA2736965C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04019248.6 2004-08-13
EP04019248 2004-08-13
PCT/EP2005/053602 WO2006015942A1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2736965A Division CA2736965C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Publications (2)

Publication Number Publication Date
CA2572729A1 CA2572729A1 (en) 2006-02-16
CA2572729C true CA2572729C (en) 2011-06-21

Family

ID=34926161

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2572729A Active CA2572729C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2736965A Active CA2736965C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2572864A Expired - Fee Related CA2572864C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2736965A Active CA2736965C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2572864A Expired - Fee Related CA2572864C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Country Status (32)

Country Link
US (6) US20060051417A1 (en)
EP (6) EP2368545A1 (en)
JP (5) JP4785847B2 (en)
KR (2) KR101406767B1 (en)
CN (4) CN101849921A (en)
AR (1) AR050602A1 (en)
AT (2) ATE486588T1 (en)
AU (3) AU2005271192B2 (en)
BR (2) BRPI0513847A (en)
CA (3) CA2572729C (en)
CY (2) CY1111713T1 (en)
DE (1) DE602005024570D1 (en)
DK (2) DK1789021T4 (en)
EA (4) EA200900930A1 (en)
EC (2) ECSP077241A (en)
ES (2) ES2355735T5 (en)
HK (2) HK1104974A1 (en)
HR (2) HRP20100682T4 (en)
IL (3) IL181283A (en)
ME (2) ME01442B (en)
MX (2) MX2007001706A (en)
NO (2) NO342453B1 (en)
NZ (3) NZ589267A (en)
PL (2) PL1789021T3 (en)
PT (2) PT1781260E (en)
RS (2) RS51527B2 (en)
SG (1) SG148996A1 (en)
SI (2) SI1789021T1 (en)
TW (2) TWI347850B (en)
UA (3) UA86831C2 (en)
WO (2) WO2006015944A2 (en)
ZA (2) ZA200700086B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (en) * 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
MX2007001850A (en) 2004-08-13 2007-03-28 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof.
KR101406767B1 (en) * 2004-08-13 2014-06-20 베링거 인겔하임 인터내셔날 게엠베하 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1781265B1 (en) * 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
CN101299992A (en) * 2005-11-04 2008-11-05 伊士曼化工公司 Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
FR2900823B1 (en) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile NEW FORM OF ADMINISTRATION OF RACECADOTRIL.
PL2026803T3 (en) * 2006-05-16 2012-05-31 Knopp Neurosciences Inc Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
MX2009001884A (en) * 2006-08-24 2009-03-06 Boehringer Ingelheim Pharma Process for preparing pramipexole dihydrochloride tablets with high storage stability.
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (en) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． Synthesis of chiral purified substituted benzothiazolediamine
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
WO2008129043A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
WO2010022140A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
MX2012000096A (en) * 2009-07-02 2012-04-02 Supernus Pharmaceuticals Inc A method of treatment of a neurological disorder.
EP2525786A2 (en) 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
US20120059013A1 (en) * 2010-03-09 2012-03-08 Boehringer Ingelheim International Gmbh Method of treating early morning akinesia in subjects having parkinson's disease
TR201001862A1 (en) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Controlled release pramipexole formulations.
KR101406265B1 (en) * 2010-03-17 2014-06-12 영진약품공업주식회사 Pharmaceutical composition of Pramipexole with improved stability and method for preparing thereof
US20130209553A1 (en) 2010-04-15 2013-08-15 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
EP2380560A1 (en) * 2010-04-22 2011-10-26 ratiopharm GmbH Matrix tablets containing pramipexol
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP2013526601A (en) 2010-05-24 2013-06-24 ルピン・リミテッド Sustained release formulation of pramipexole
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
KR101439635B1 (en) * 2011-11-01 2014-09-11 대원제약주식회사 Pharmaceutical composition containing entecavir having enhanced stability and preparation method thereof
CN102406626B (en) * 2011-12-02 2013-08-28 深圳海王药业有限公司 Pramipexole hydrochloride slow release tablet and preparation method thereof
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2806861A1 (en) * 2012-01-23 2014-12-03 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
CN102836137A (en) * 2012-09-21 2012-12-26 山东齐都药业有限公司 Pramipexole dihydrochloride slow-release tablet with high content uniformity and preparation method thereof
EP2732812A1 (en) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexole retard tablet formulation
CN103435571B (en) * 2012-11-22 2015-12-09 北京三泉医药技术有限公司 Tetrahydrobenzothiazderivative derivative and preparation method thereof
CN102988319B (en) * 2012-12-10 2014-10-08 成都欣捷高新技术开发有限公司 III crystal form pramipexole hydrochloride tablet and preparation method thereof
CN103040781B (en) * 2013-01-04 2014-07-16 杭州朱养心药业有限公司 Pramipexole dihydrochloride tablet composition and preparation method thereof
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN104161735A (en) * 2013-05-19 2014-11-26 成都康弘药业集团股份有限公司 Sustained-release preparation containing pramipexole hydrochloride and preparation method thereof
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN103520128B (en) 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 A kind of sustained-release tablet of Pramipexole, preparation method and its usage
CN105456216B (en) * 2014-08-18 2019-11-05 江苏神龙药业股份有限公司 Pramipexole hydrochloride slow release tablet composition and preparation method thereof
JP2016113441A (en) * 2014-10-27 2016-06-23 大原薬品工業株式会社 Tablet in which release containing pramipexole dihydrochloride monohydrate is extended
CN105796519A (en) * 2014-12-30 2016-07-27 浙江京新药业股份有限公司 Pramipexole dihydrochloride sustained-release tablet and preparation method thereof
CN104606162B (en) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 A kind of body of Pramipexole dihydrochloride slow releasing preparation and preparation method thereof
JP6366547B2 (en) * 2015-08-03 2018-08-01 大原薬品工業株式会社 Pramipexole formulation package with improved photostability
CN105380917B (en) * 2015-08-24 2019-01-15 江苏神华药业有限公司 A kind of body of Pramipexole dihydrochloride sustained release tablets and preparation method thereof
CN106983729B (en) * 2016-01-21 2021-02-26 北京北大维信生物科技有限公司 Pramipexole sustained release tablet and preparation method thereof
CN107951853B (en) * 2016-10-17 2022-04-08 海思科制药(眉山)有限公司 Pramipexole dihydrochloride sustained-release pharmaceutical composition and preparation method thereof
CN108785263B (en) * 2017-04-26 2021-06-29 江苏恒瑞医药股份有限公司 Solid pharmaceutical composition of pramipexole or pharmaceutical salt thereof and preparation method thereof
JP7223744B2 (en) * 2017-07-26 2023-02-16 ティージーエックス ソフト チュー エルエルシー Starch-free soft chews for veterinary use
US11234961B2 (en) 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
CN109966256B (en) * 2017-12-28 2022-08-02 北京北大维信生物科技有限公司 Pramipexole sustained-release pharmaceutical composition, preparation method and application thereof
CN108159007B (en) * 2017-12-29 2021-04-16 成都百裕制药股份有限公司 Pramipexole dihydrochloride sustained-release preparation and preparation method thereof
WO2019207606A1 (en) * 2018-04-27 2019-10-31 Rubicon Research Private Limited Extended release compositions and process for preparation
CN112704668B (en) * 2021-01-12 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 Pramipexole dihydrochloride sustained-release composition
CN112716908A (en) * 2021-02-03 2021-04-30 上海雅本化学有限公司 Preparation process of pramipexole
CN113876729B (en) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 Pramipexole dihydrochloride sustained-release tablet and preparation method thereof
CN114869854A (en) * 2022-04-18 2022-08-09 华裕(无锡)制药有限公司 Pramipexole dihydrochloride sustained-release tablet with high bioequivalence and preparation method thereof

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
BE604564A (en) * 1960-06-06
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (en) * 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
CH649215A5 (en) 1981-04-29 1985-05-15 Hoffmann La Roche PHARMACEUTICAL PREPARATIONS.
SE8103843L (en) * 1981-06-18 1982-12-19 Astra Laekemedel Ab PHARMACEUTICAL MIXTURE
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
ATE45735T1 (en) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K TETRAHYDRO-BENZTHIAZOLE, THEIR PRODUCTION AND USE AS INTERMEDIATE OR MEDICINAL PRODUCTS.
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4666612A (en) * 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
FR2653337B1 (en) 1989-10-23 1992-02-07 Dow Corning Sa SUSTAINED RELEASE ELEMENT AND METHOD FOR MANUFACTURING THE SAME.
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04234812A (en) 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd Granule for long-acting pharmaceutical preparation
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5731338A (en) * 1992-07-02 1998-03-24 Oramed, Inc. Controlled release pilocarpine delivery system
AU682827B2 (en) 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
DE4241013A1 (en) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole as antidepressant drug
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4432757A1 (en) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmaceutical preparation containing metformin and process for its preparation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ID23503A (en) 1997-07-01 2000-04-27 Pfizer SERTRALINA SALES AND DETAILED FORMS OF SERTRALINA
DK1009387T3 (en) 1997-07-02 2006-08-14 Euro Celtique Sa Long-release stabilized tramadol formulations
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (en) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DK1019022T4 (en) 1997-09-29 2010-11-08 Novartis Ag Perforated microparticles and their method of use
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (en) * 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
HUP0101043A3 (en) 1998-03-11 2002-02-28 Smithkline Beecham Corp Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation
EA004474B1 (en) 1998-05-15 2004-04-29 Фармация Энд Апджон Компани Combined treating of cns diseases, especially parkinson's disease by combined administration of cabergoline and pramipexole
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
DE19906290A1 (en) 1999-02-15 2000-08-17 Falk Pharma Gmbh Orally administered medicament for treating colon cancer comprises ursodesoxycholic acid in gastric fluid resistant coating to provide direct topical action at target site
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
PL198797B1 (en) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
DE19927688A1 (en) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
EP2090312A1 (en) 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating attention deficit disorder
AU779955B2 (en) * 1999-07-13 2005-02-24 Alpha Research Group, Llc Compositions and methods for the treatment of Parkinson's disease
AP2002002410A0 (en) 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
CO5210862A1 (en) 1999-09-15 2002-10-30 Alza Corp DOSAGE FORMS AND METHODS TO PROVIDE REBOXETINE EFFECTIVE THERAPY WITH DOSAGE ONCE A DAY
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
MXPA02003976A (en) * 1999-10-19 2003-09-25 Nps Pharma Inc Sustained-release formulations for treating cns-mediated disorders.
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NZ519466A (en) * 1999-12-22 2004-02-27 Pharmacia Corp Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en) * 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
PE20011074A1 (en) * 2000-02-23 2001-10-04 Upjohn Co USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
AU2001286418A1 (en) * 2000-08-08 2002-02-18 Teva Pharmaceutical Industries Ltd. Stable pergolide mesylate and process for making same
ES2187249B1 (en) * 2000-09-18 2004-09-16 Synthon Bv PROCEDURE FOR THE PREPARATION OF 2-AMINO-6- (RENT) AMINO-4,5,6,7-TETRAHYDROBENZOTIAZOLES.
SE0004671D0 (en) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
US20030032661A1 (en) * 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
DE10138275A1 (en) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Connections to eliminate anhedonia
BR0215262A (en) 2001-12-20 2004-12-28 Pharmacia Corp Zero-order sustained release dosage forms and manufacturing process
CA2474613A1 (en) * 2002-03-04 2003-09-18 Jacques-Pierre Moreau Sustained release drug formulations containing a carrier peptide
SI2425824T1 (en) 2002-04-05 2017-06-30 Mundipharma Medical Cee Gmbh Pharmaceutical preparation containing oxycodone and naloxone
EA007156B1 (en) * 2002-04-15 2006-08-25 Адамс Лэборетриз, Инк. Sustained release of guaifenesin combination drugs
US20030215498A1 (en) * 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
BR0311693A (en) * 2002-06-10 2005-03-22 Wyeth Corp O-desmethyl-venlafaxine salt
JP2005537240A (en) 2002-06-27 2005-12-08 シラグ・アクチエンゲゼルシヤフト Spherical pellet containing active ingredients soluble in water
JP4478413B2 (en) * 2002-07-11 2010-06-09 武田薬品工業株式会社 Manufacturing method of coated preparation
FR2842734A1 (en) * 2002-07-24 2004-01-30 Ethypharm Sa METHOD FOR DECREASING THE VARIABILITY OF THE BIOAVAILABILITY OF AN ORAL MEDICINAL PRODUCT AND ORAL PHARMACEUTICAL COMPOSITIONS
US20070196481A1 (en) 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
JP2005538105A (en) * 2002-07-25 2005-12-15 ファルマシア・コーポレーション Method for producing a solid dosage form coated with two layers comprising a water-insoluble polymer and a water-soluble pore-forming substance
PA8578501A1 (en) * 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004080440A1 (en) * 2003-03-11 2004-09-23 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
BRPI0408999A (en) 2003-04-04 2006-03-28 Pharmacia Corp compressed prolonged oral release multiparticulate tablets
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
MX2007001850A (en) * 2004-08-13 2007-03-28 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof.
KR101406767B1 (en) * 2004-08-13 2014-06-20 베링거 인겔하임 인터내셔날 게엠베하 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
US20070148238A1 (en) 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
ATE444750T1 (en) 2005-08-15 2009-10-15 Univ Virginia NEURORESTORATION WITH R(+) PRAMIPEXOL
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090881A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
AR062321A1 (en) * 2006-08-25 2008-10-29 Boehringer Ingelheim Int CONTROLLED RELEASE SYSTEM AND METHOD TO MANUFACTURE

Also Published As

Publication number Publication date
AU2005271194B2 (en) 2011-11-24
NO20070719L (en) 2007-03-02
BRPI0513846A (en) 2008-05-20
EP1781260B1 (en) 2010-11-03
CA2572864A1 (en) 2006-02-16
US8377977B2 (en) 2013-02-19
HRP20120068T4 (en) 2015-02-13
AU2011250676A1 (en) 2011-12-01
WO2006015942A1 (en) 2006-02-16
RS52057B (en) 2012-04-30
ECSP077241A (en) 2007-03-29
TW200618821A (en) 2006-06-16
JP2009102409A (en) 2009-05-14
EP1781260A1 (en) 2007-05-09
CN101849921A (en) 2010-10-06
EA015335B1 (en) 2011-06-30
CN101005831A (en) 2007-07-25
ES2355735T3 (en) 2011-03-30
DK1789021T4 (en) 2014-11-10
JP4785847B2 (en) 2011-10-05
UA93608C2 (en) 2011-02-25
EP2286801A3 (en) 2012-05-09
CN101005830B (en) 2010-09-29
TWI347850B (en) 2011-09-01
US20060198887A1 (en) 2006-09-07
EP2368545A1 (en) 2011-09-28
AU2005271192B2 (en) 2011-11-17
KR20070052300A (en) 2007-05-21
US20060051417A1 (en) 2006-03-09
CN101005831B (en) 2010-11-10
ATE532503T1 (en) 2011-11-15
PT1789021E (en) 2011-12-22
CY1112268T1 (en) 2015-12-09
NZ553561A (en) 2010-12-24
ZA200700086B (en) 2008-02-27
KR101406767B1 (en) 2014-06-20
US20090281153A1 (en) 2009-11-12
ZA200700085B (en) 2008-02-27
SI1789021T1 (en) 2012-02-29
IL181282A (en) 2012-10-31
HK1104973A1 (en) 2008-02-01
JP2011084577A (en) 2011-04-28
RS51527B (en) 2011-06-30
HRP20100682T1 (en) 2011-01-31
WO2006015944A2 (en) 2006-02-16
EA201001083A1 (en) 2011-08-30
HRP20120068T1 (en) 2012-02-29
CY1111713T1 (en) 2015-10-07
ECSP077242A (en) 2007-05-30
HRP20100682T4 (en) 2014-08-01
NO342453B1 (en) 2018-05-22
IL220313A0 (en) 2012-07-31
EA200700201A1 (en) 2007-08-31
ME01316B (en) 2013-12-20
US7695734B2 (en) 2010-04-13
PL1789021T3 (en) 2012-04-30
CA2572729A1 (en) 2006-02-16
BRPI0513847A (en) 2008-05-20
RS52057B2 (en) 2018-03-30
AU2005271194A1 (en) 2006-02-16
TW201100126A (en) 2011-01-01
IL181282A0 (en) 2007-07-04
ATE486588T1 (en) 2010-11-15
EA016850B1 (en) 2012-08-30
DE602005024570D1 (en) 2010-12-16
IL181283A0 (en) 2007-07-04
NZ589267A (en) 2012-06-29
ES2377214T3 (en) 2012-03-23
PL1781260T5 (en) 2014-09-30
SG148996A1 (en) 2009-01-29
JP2008509194A (en) 2008-03-27
WO2006015944A3 (en) 2007-02-08
CN101005830A (en) 2007-07-25
PT1781260E (en) 2010-12-20
KR20070046172A (en) 2007-05-02
DK1789021T3 (en) 2012-03-05
RS51527B2 (en) 2018-02-28
EP1789021B1 (en) 2011-11-09
JP4757872B2 (en) 2011-08-24
IL181283A (en) 2013-12-31
US20140335175A1 (en) 2014-11-13
DK1781260T4 (en) 2014-06-23
UA86831C2 (en) 2009-05-25
EP2286801A2 (en) 2011-02-23
US20090182024A1 (en) 2009-07-16
CA2736965A1 (en) 2006-02-16
NZ553587A (en) 2010-12-24
NO20070733L (en) 2007-03-06
EP1781260B9 (en) 2011-02-16
EP1789021A2 (en) 2007-05-30
EP1781260B2 (en) 2014-04-02
JP2011126916A (en) 2011-06-30
ME01442B (en) 2013-12-20
CA2572864C (en) 2014-02-11
AU2005271192A1 (en) 2006-02-16
SI1781260T1 (en) 2011-02-28
TWI347199B (en) 2011-08-21
EP1789021B2 (en) 2014-10-08
MX2007001765A (en) 2007-04-20
SI1781260T2 (en) 2014-08-29
CA2736965C (en) 2014-02-18
CN101884626A (en) 2010-11-17
EP2135602A1 (en) 2009-12-23
US20130274300A1 (en) 2013-10-17
EA200900930A1 (en) 2009-12-30
DK1781260T3 (en) 2011-02-21
UA89052C2 (en) 2009-12-25
ES2355735T5 (en) 2014-06-27
HK1104974A1 (en) 2008-02-01
MX2007001706A (en) 2007-04-12
PL1781260T3 (en) 2011-04-29
EA200700132A1 (en) 2007-08-31
JP2008509192A (en) 2008-03-27
AR050602A1 (en) 2006-11-08
EP2345407A1 (en) 2011-07-20
KR101052436B1 (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CA2572729C (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
AU2011244983A1 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
EEER Examination request